Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 1
1959 1
1961 2
1962 1
1963 2
1964 4
1965 1
1966 1
1967 4
1968 2
1969 5
1970 7
1971 1
1972 3
1973 4
1974 2
1975 3
1976 7
1977 7
1978 9
1979 13
1980 4
1981 15
1982 13
1983 4
1984 11
1985 18
1986 14
1987 15
1988 14
1989 21
1990 14
1991 26
1992 21
1993 15
1994 23
1995 18
1996 15
1997 11
1998 16
1999 32
2000 27
2001 30
2002 32
2003 41
2004 46
2005 57
2006 57
2007 63
2008 46
2009 61
2010 54
2011 84
2012 85
2013 93
2014 100
2015 75
2016 93
2017 100
2018 89
2019 112
2020 133
2021 143
2022 112
2023 118
2024 40

Text availability

Article attribute

Article type

Publication date

Search Results

2,054 results

Results by year

Filters applied: . Clear all
Page 1
PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes.
Nagasaki J, Inozume T, Sax N, Ariyasu R, Ishikawa M, Yamashita K, Kawazu M, Ueno T, Irie T, Tanji E, Morinaga T, Honobe A, Ohnuma T, Yoshino M, Iwata T, Kawase K, Sasaki K, Hanazawa T, Kochin V, Kawamura T, Matsue H, Hino M, Mano H, Suzuki Y, Nishikawa H, Togashi Y. Nagasaki J, et al. Among authors: iwata t. Cell Rep. 2022 Feb 1;38(5):110331. doi: 10.1016/j.celrep.2022.110331. Cell Rep. 2022. PMID: 35108529 Free article.
Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial.
Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Sattar N, Brueckmann M, Jamal W, Cotton D, Iwata T, Zannad F; EMPEROR-Reduced Trial Committees and Investigators. Packer M, et al. Among authors: iwata t. J Am Coll Cardiol. 2021 Mar 23;77(11):1381-1392. doi: 10.1016/j.jacc.2021.01.033. J Am Coll Cardiol. 2021. PMID: 33736819 Free article. Clinical Trial.
Genetic characterization of 1210 Japanese pedigrees with inherited retinal diseases by whole-exome sequencing.
Suga A, Yoshitake K, Minematsu N, Tsunoda K, Fujinami K, Miyake Y, Kuniyoshi K, Hayashi T, Mizobuchi K, Ueno S, Terasaki H, Kominami T, Nao-I N, Mawatari G, Mizota A, Shinoda K, Kondo M, Kato K, Sekiryu T, Nakamura M, Kusuhara S, Yamamoto H, Yamamoto S, Mochizuki K, Kondo H, Matsushita I, Kameya S, Fukuchi T, Hatase T, Horiguchi M, Shimada Y, Tanikawa A, Yamamoto S, Miura G, Ito N, Murakami A, Fujimaki T, Hotta Y, Tanaka K, Iwata T. Suga A, et al. Among authors: iwata t. Hum Mutat. 2022 Dec;43(12):2251-2264. doi: 10.1002/humu.24492. Epub 2022 Nov 7. Hum Mutat. 2022. PMID: 36284460
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y, Yaguchi T, Kubo A, Iwata T, Morii K, Kato D, Ohta S, Satomi R, Yamamoto Y, Oyamada Y, Ouchi K, Takahashi S, Ishioka C, Matoba R, Suematsu M, Kawakami Y. Katoh Y, et al. Among authors: iwata t. J Immunother Cancer. 2022 Jul;10(7):e004616. doi: 10.1136/jitc-2022-004616. J Immunother Cancer. 2022. PMID: 35793868 Free PMC article.
Efficacy of Empagliflozin in Patients With Heart Failure Across Kidney Risk Categories.
Butler J, Packer M, Siddiqi TJ, Böhm M, Brueckmann M, Januzzi JL, Verma S, Gergei I, Iwata T, Wanner C, Ferreira JP, Pocock SJ, Filippatos G, Anker SD, Zannad F. Butler J, et al. Among authors: iwata t. J Am Coll Cardiol. 2023 May 16;81(19):1902-1914. doi: 10.1016/j.jacc.2023.03.390. J Am Coll Cardiol. 2023. PMID: 37164523 Free article.
Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age.
Böhm M, Butler J, Filippatos G, Ferreira JP, Pocock SJ, Abdin A, Mahfoud F, Brueckmann M, Gollop ND, Iwata T, Ponikowski P, Wanner C, Zannad F, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Böhm M, et al. Among authors: iwata t. J Am Coll Cardiol. 2022 Jul 5;80(1):1-18. doi: 10.1016/j.jacc.2022.04.040. J Am Coll Cardiol. 2022. PMID: 35772911 Free article. Clinical Trial.
Empagliflozin in heart failure with preserved ejection fraction with and without atrial fibrillation.
Filippatos G, Farmakis D, Butler J, Zannad F, Ferreira JP, Ofstad AP, Iwata T, Brueckmann M, Pocock SJ, Packer M, Anker SD; EMPEROR-Preserved Trial Committees and Investigators. Filippatos G, et al. Among authors: iwata t. Eur J Heart Fail. 2023 Jul;25(7):970-977. doi: 10.1002/ejhf.2861. Epub 2023 May 8. Eur J Heart Fail. 2023. PMID: 37062866 Clinical Trial.
Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826.
Nishio S, Yonemori K, Usami T, Minobe S, Yunokawa M, Iwata T, Okamoto A, Aoki Y, Itamochi H, Takekuma M, Harano K, Yamamoto K, Maruko T, Ugai H, Tekin C, Colombo N, Fujiwara K, Hasegawa K, Ushijima K. Nishio S, et al. Among authors: iwata t. Cancer Sci. 2022 Nov;113(11):3877-3887. doi: 10.1111/cas.15479. Epub 2022 Sep 15. Cancer Sci. 2022. PMID: 35792064 Free PMC article. Clinical Trial.
2,054 results